Illumina : Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT

--(BUSINESS WIRE)--Jan. 7, 2016-- (NASDAQ: ILMN) today announced that it has filed two patent infringement suits in . The patents asserted use cell-free fetal DNA for non-invasive prenatal testing (NIPT).

The first suit was filed against , , and in the , Chancery Division in the . The suit accuses and TDL Genetics' use of the Harmony NIPT test supplied by Ariosa of infringing European Patent 0 994 963.

The second suit was filed against Centrum Badań Sp z o.o. and Medgenetix Sp z o.o. in the Regional Court in . The suit accuses Centrum and Medgenetix's use of the Iona® NIPT test supplied by of infringing European Patent 2 183 693.

is seeking all available remedies, including damages and injunctive relief.

These new lawsuits follow suits previously filed against Ariosa in and Premaitha in the .

About

is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

View source version on businesswire.com:http://www.businesswire.com/news/home/20160107006103/en/

Source:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
[e-mail]
or
Media:
Jennifer Temple
858-882-6822
[e-mail]
or
David Robertson, Europe, Middle East and Africa
[phone]
[e-mail]